Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Botulinum purified neurotoxin, Type A · 1 trial · 1 indication
The primary safety analysis was the calculation of the proportion of subjects with at least one adverse event that occurred from Day 0 through Day 365.
| Arm | Type | Description |
|---|---|---|
| Botulinum neurotoxin, Type A | EXPERIMENTAL | DWP-450 (Botulinum purified neurotoxin, Type A) Injection |
| Name | Type | Description |
|---|---|---|
| Botulinum purified neurotoxin, Type A | BIOLOGICAL | The subject is to be injected intra-muscularly into a total of five sites: the mid-line of the procures muscle, the inferomedial aspect of each corrugator muscle and the superior middle aspect of each corrugator, at least 1 cm above the bony orbital rim. Each site is injected with 0.1 ml (4U), for a total of 20 U and 0.5 ml. |
Inclusion Criteria (A subject must meet all of the following inclusion criteria in order to be eligible for enrollment in the study): * Subjects must be an adult 18 years of age or over * Subject is able to provide informed consent and comply with study instructions * Subject has moderate to severe...
Botulinum purified neurotoxin, Type A is being developed for the treatment of glabellar frown lines, the vertical lines that form between the eyebrows. It is an investigational injectable therapy in Phase 2 clinical development for this dermatologic aesthetic indication.
Botulinum purified neurotoxin, Type A targets SNAP25, a hydrolytic enzyme involved in neurotransmitter release. By acting on SNAP25, the agent is designed to affect the signaling that underlies muscle contraction in the treated area.
Evolus, Inc. (ticker EOLS) is the developer of botulinum purified neurotoxin, Type A. The company is advancing the asset for glabellar frown lines within the dermatology therapeutic area.
Botulinum purified neurotoxin, Type A is in Phase 2 clinical development. It is an investigational therapy and has not been approved by the FDA for glabellar frown lines or any other indication.
Botulinum purified neurotoxin, Type A has been studied in one completed Phase 2 trial, NCT02184988, titled Safety Study of DWP-450 (Botulinum Purified Neurotoxin, Type A) Injection to Treat Glabellar Lines. The trial enrolled 352 participants in the United States and has completed.
Yes. DWP-450 is an alternative name for botulinum purified neurotoxin, Type A. The Phase 2 trial NCT02184988 refers to the asset as DWP-450, so searches for either name point to the same investigational product developed by Evolus.